Compare Becton Dickinson and Co (BDX) vs Snowflake Inc (SNOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Snowflake Inc — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while Snowflake Inc trades at $276.12 (market cap $95.64B). The key difference: Snowflake Inc is far larger — about 2.3× Becton Dickinson and Co's market cap, and Becton Dickinson and Co pays a 2.79% dividend while Snowflake Inc pays none. Which is the better fit depends on your goals.
| BDX | SNOW | |
|---|---|---|
Market Cap | $41.51B | $95.64B |
Sector | Health | Technology |
52-Week High | $185.39 | $280.16 |
52-Week Low | $135.49 | $121.11 |
Enterprise Value | $57.97B | $95.46B |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
Snowflake (SNOW) trades at $268.65, up 2.75% with strong technical momentum and bullish moving average signals. The company demonstrates robust revenue growth, reaching $3.63 billion in 2025, though remains unprofitable with a -23.79% net margin. Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $0.39 surpassing the $0.3193 estimate. Analyst sentiment remains overwhelmingly positive with 42 buy ratings and a $297.35 consensus price target, representing 10.7% upside potential.
Snowflake's outlook remains promising due to accelerating AI Data Cloud adoption and 30% revenue growth targets, but faces risks from premium valuation (P/S 18.19), intense cloud competition, and persistent profitability challenges. The stock's current technical positioning near pivot point resistance at $269 requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →
